WS #14687
Biotech stocks are finding support through clinical catalysts rather than macro beta. Kyverna Therapeutics reported sustained clinical benefit for its single-dose Miv-Cel therapy, reinforcing the potential for curative treatments in rare diseases. Additionally, US regulators have backed a multi-cancer blood test, signaling a maturation of early detection technologies. These developments are driving capital rotation into high-conviction clinical-stage names.
Biotech Clinical Catalysts
Biotech stocks are finding support through clinical catalysts rather than macro beta. Kyverna Therapeutics reported sustained clinical benefit for its single-dose Miv-Cel therapy, reinforcing the potential for curative treatments in rare diseases. Additionally, US regulators have backed a multi-cancer blood test, signaling a maturation of early detection technologies. These developments are driving capital rotation into high-conviction clinical-stage names.